Immunocore Holdings plc - American Depositary Shares (IMCR)

30.99
+2.59 (9.12%)
NASDAQ · Last Trade: Nov 6th, 5:44 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close28.40
Open29.95
Bid27.51
Ask40.33
Day's Range29.15 - 31.28
52 Week Range27.50 - 40.71
Volume1,526,513
Market Cap1.36B
PE Ratio (TTM)-83.76
EPS (TTM)-0.4
Dividend & YieldN/A (N/A)
1 Month Average Volume498,559

Chart

About Immunocore Holdings plc - American Depositary Shares (IMCR)

Immunocore Holdings Plc is a biotechnology company that specializes in the development of innovative T cell receptor-based therapies to treat a range of diseases, including cancer and autoimmune conditions. The company focuses on harnessing the power of the immune system by creating treatments designed to engage T cells, which play a critical role in the body's defense against diseases. Through its proprietary technology platform, Immunocore aims to develop a new class of drugs that can effectively target and destroy diseased cells while minimizing impact on healthy tissues. The company's research and clinical efforts are driven by a commitment to advancing science and improving patient outcomes in areas of significant unmet medical need. Read More

News & Press Releases

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
By Immunocore Holdings plc · Via GlobeNewswire · November 6, 2026
Immunocore reports third quarter financial results and provides a business update
KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
By Immunocore Holdings plc · Via GlobeNewswire · November 6, 2026
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
By Immunocore Holdings plc · Via GlobeNewswire · October 29, 2026
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces first patient dosed in the Phase 1 trial of
By Immunocore Holdings plc · Via GlobeNewswire · October 15, 2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
By Immunocore Holdings plc · Via GlobeNewswire · September 14, 2026
Immunocore (NASDAQ:IMCR) Q2 Revenue Beats but EPS Misses, Shares Tumblechartmill.com
Via Chartmill · August 6, 2026
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences
By Immunocore Holdings plc · Via GlobeNewswire · September 1, 2026
Immunocore Q2 Earnings Call Highlightsmarketbeat.com
Immunocore (NASDAQ:IMCR) reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV and Type 1 diabetes. The company recorded $223 million in KIMMTRAK net sales during the first half
Via MarketBeat · August 6, 2026
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update
By Immunocore Holdings plc · Via GlobeNewswire · August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
By Immunocore Holdings plc · Via GlobeNewswire · July 30, 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
By Immunocore Holdings plc · Via GlobeNewswire · May 31, 2026
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update
By Immunocore Holdings plc · Via GlobeNewswire · May 6, 2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
By Immunocore Holdings plc · Via GlobeNewswire · April 19, 2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
By Immunocore Holdings plc · Via GlobeNewswire · April 6, 2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
By Immunocore Holdings plc · Via GlobeNewswire · March 17, 2026
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences
By Immunocore Holdings plc · Via GlobeNewswire · March 3, 2026
Immunocore (IMCR) Q4 2025 Earnings Call Transcriptfool.com
Immunocore (IMCR) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 25, 2026
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
By Immunocore Holdings plc · Via GlobeNewswire · February 25, 2026
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
By Immunocore Holdings plc · Via GlobeNewswire · February 18, 2026
Immunocore announces R&D leadership evolution
Immunocore announces R&D leadership evolution
By Immunocore Holdings plc · Via GlobeNewswire · January 30, 2026
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
By Immunocore Holdings plc · Via GlobeNewswire · January 9, 2026
Immunocore (IMCR) Q2 2025 Earnings Call Transcriptfool.com
Immunocore (IMCR) Q2 2025 Earnings Call Transcript
Via The Motley Fool · November 27, 2025
Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
By Immunocore Holdings plc · Via GlobeNewswire · November 10, 2025
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity
By Immunocore Holdings plc · Via GlobeNewswire · November 7, 2025
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update
By Immunocore Holdings plc · Via GlobeNewswire · November 6, 2025